Vaxil Bio Ltd (VXL) - Net Assets
Based on the latest financial reports, Vaxil Bio Ltd (VXL) has net assets worth CA$667.00K CAD (≈ $482.50K USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$675.00K ≈ $488.28K USD) and total liabilities (CA$8.00K ≈ $5.79K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check VXL intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$667.00K |
| % of Total Assets | 98.81% |
| Annual Growth Rate | 2.21% |
| 5-Year Change | -10.95% |
| 10-Year Change | N/A |
| Growth Volatility | 217.71 |
Vaxil Bio Ltd - Net Assets Trend (2009–2024)
This chart illustrates how Vaxil Bio Ltd's net assets have evolved over time, based on quarterly financial data. See Vaxil Bio Ltd (VXL) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Vaxil Bio Ltd (2009–2024)
The table below shows the annual net assets of Vaxil Bio Ltd from 2009 to 2024. For live valuation and market cap data, see VXL market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CA$716.00K ≈ $517.94K |
-19.64% |
| 2023-12-31 | CA$891.00K ≈ $644.54K |
-21.57% |
| 2022-12-31 | CA$1.14 Million ≈ $821.77K |
-33.18% |
| 2021-12-31 | CA$1.70 Million ≈ $1.23 Million |
+111.44% |
| 2020-12-31 | CA$804.00K ≈ $581.60K |
+237.91% |
| 2019-12-31 | CA$-583.00K ≈ $-421.73K |
-234.02% |
| 2018-12-31 | CA$435.00K ≈ $314.67K |
+189.32% |
| 2017-12-31 | CA$-487.00K ≈ $-352.29K |
-174.24% |
| 2016-12-31 | CA$656.00K ≈ $474.54K |
+402.30% |
| 2015-12-31 | CA$-217.00K ≈ $-156.97K |
-729.37% |
| 2014-12-31 | CA$34.48K ≈ $24.94K |
-81.65% |
| 2013-12-31 | CA$187.94K ≈ $135.95K |
+160.49% |
| 2012-12-31 | CA$72.15K ≈ $52.19K |
-72.68% |
| 2011-12-31 | CA$264.09K ≈ $191.04K |
-61.28% |
| 2010-12-31 | CA$682.06K ≈ $493.39K |
+32.21% |
| 2009-12-31 | CA$515.90K ≈ $373.20K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Vaxil Bio Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1937407300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$20.25 Million | 2828.35% |
| Total Equity | CA$716.00K | 100.00% |
Vaxil Bio Ltd Competitors by Market Cap
The table below lists competitors of Vaxil Bio Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ORUM
KQ:475830
|
$411.35K |
|
H&G High Conviction Ltd
AU:HCF
|
$411.94K |
|
LEGIBLE INC.
F:D0T
|
$412.41K |
|
Fashion Bel Air S.A
PA:ALFBA
|
$414.00K |
|
Everyman Media Group plc
LSE:EMAN
|
$410.48K |
|
Quintegra Solutions Limited
NSE:QUINTEGRA
|
$408.87K |
|
Synectics plc
LSE:SNX
|
$408.04K |
|
in Style Group PLC
LSE:ITS
|
$406.88K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vaxil Bio Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 891,000 to 716,000, a change of -175,000 (-19.6%).
- Net loss of 178,000 reduced equity.
- Other comprehensive income decreased equity by 4,174,000.
- Other factors increased equity by 4,177,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-178.00K | -24.86% |
| Other Comprehensive Income | CA$-4.17 Million | -582.96% |
| Other Changes | CA$4.18 Million | +583.38% |
| Total Change | CA$- | -19.64% |
Book Value vs Market Value Analysis
This analysis compares Vaxil Bio Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.88x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.06x to 0.88x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | CA$3.99 | CA$0.23 | x |
| 2010-12-31 | CA$1.17 | CA$0.23 | x |
| 2011-12-31 | CA$0.34 | CA$0.23 | x |
| 2012-12-31 | CA$0.08 | CA$0.23 | x |
| 2013-12-31 | CA$0.06 | CA$0.23 | x |
| 2014-12-31 | CA$2.45 | CA$0.23 | x |
| 2015-12-31 | CA$-0.02 | CA$0.23 | x |
| 2016-12-31 | CA$0.02 | CA$0.23 | x |
| 2017-12-31 | CA$-0.01 | CA$0.23 | x |
| 2018-12-31 | CA$0.01 | CA$0.23 | x |
| 2019-12-31 | CA$-0.01 | CA$0.23 | x |
| 2020-12-31 | CA$0.01 | CA$0.23 | x |
| 2021-12-31 | CA$0.01 | CA$0.23 | x |
| 2022-12-31 | CA$0.01 | CA$0.23 | x |
| 2023-12-31 | CA$0.01 | CA$0.23 | x |
| 2024-12-31 | CA$0.26 | CA$0.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vaxil Bio Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.02x
- Recent ROE (-24.86%) is above the historical average (-142.57%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -31.19% | 0.00% | 0.00x | 1.06x | CA$-212.52K |
| 2010 | -55.97% | 0.00% | 0.00x | 1.06x | CA$-449.95K |
| 2011 | -196.69% | 0.00% | 0.00x | 1.38x | CA$-545.86K |
| 2012 | -593.64% | 0.00% | 0.00x | 3.76x | CA$-435.50K |
| 2013 | -161.07% | 0.00% | 0.00x | 1.35x | CA$-321.50K |
| 2014 | -5.37% | 0.00% | 0.00x | 3.36x | CA$-5.30K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-1.05 Million |
| 2016 | -691.92% | 0.00% | 0.00x | 1.86x | CA$-4.60 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-1.75 Million |
| 2018 | -240.69% | 0.00% | 0.00x | 2.05x | CA$-1.09 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-1.11 Million |
| 2020 | -170.27% | 0.00% | 0.00x | 2.07x | CA$-1.45 Million |
| 2021 | -58.00% | 0.00% | 0.00x | 1.34x | CA$-1.16 Million |
| 2022 | -51.41% | 0.00% | 0.00x | 1.36x | CA$-697.60K |
| 2023 | -0.03% | 0.00% | 0.00x | 1.10x | CA$-89.35K |
| 2024 | -24.86% | 0.00% | 0.00x | 1.02x | CA$-249.60K |
Industry Comparison
This section compares Vaxil Bio Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $10,270,078
- Average return on equity (ROE) among peers: -95.85%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vaxil Bio Ltd (VXL) | CA$667.00K | -31.19% | 0.01x | $410.94K |
| Appili Therapeutics Inc (APLI) | $-3.27 Million | 0.00% | 0.00x | $1.86 Million |
| Aptose Biosciences Inc (APS) | $-757.75K | 0.00% | 0.00x | $4.06 Million |
| Arch Biopartners Inc (ARCH) | $-6.58K | 0.00% | 0.00x | $23.34 Million |
| Biomind Labs Inc (BMND) | $2.19 Million | -197.55% | 0.15x | $5.89 Million |
| Cybin Inc (CYBN) | $76.16 Million | -88.81% | 0.10x | $301.37 Million |
| Eupraxia Pharmaceuticals Inc (EPRX) | $5.11 Million | -84.55% | 0.14x | $324.98 Million |
| Devonian Health Group Inc (GSD) | $9.14 Million | -65.80% | 0.73x | $22.43 Million |
| Helix BioPharma Corp. (HBP) | $6.81 Million | -127.75% | 0.15x | $87.30 Million |
| Hemostemix Inc (HEM) | $3.39 Million | -127.82% | 0.16x | $8.18 Million |
| Universal Ibogaine Inc (IBO) | $3.94 Million | -266.20% | 0.60x | $1.13 Million |
About Vaxil Bio Ltd
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. Its lead product candidate is ImMucin, a MUC1 SP-based vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. The company is headquartered in Toronto, Canada.